Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. 4D pharma plc
  6. Company
    DDDD   GB00BJL5BR07

4D PHARMA PLC

(DDDD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo 4D pharma plc
4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.
Sales per Business
20192020Delta
Live Biotherapeutics--0.69129.2%-
GBP in Million
Sales per region
20192020Delta
United Kingdom--0.69129.2%-
GBP in Million
Managers
Name Title Age Since
Duncan Peyton Chief Executive Officer & Executive Director 50 2014
John W. Beck Chief Financial Officer 60 2021
Alexander James Stevenson, Dr. Executive Director & Chief Scientific Officer 49 2014
Imke Mulder Research Director - -
Edgardo Baracchini, Dr. Independent Non-Executive Director 60 2019
Axel Gaston Glasmacher, Dr. Non-Executive Chairman 60 2020
Alexander D. Macrae, Dr. Independent Non-Executive Director 57 2019
Katrin Rupalla, Dr. Independent Non-Executive Director 52 2020
Paul Victor Maier Independent Non-Executive Director 72 2021
Glenn Dourado Chief Business Officer - -
Members of the board
Name Title Age Since
Axel Gaston Glasmacher, Dr. Non-Executive Chairman 60 2020
Duncan Peyton Chief Executive Officer & Executive Director 50 2014
Alexander James Stevenson, Dr. Executive Director & Chief Scientific Officer 49 2014
Edgardo Baracchini, Dr. Independent Non-Executive Director 60 2019
Alexander D. Macrae, Dr. Independent Non-Executive Director 57 2019
Katrin Rupalla, Dr. Independent Non-Executive Director 52 2020
Paul Victor Maier Independent Non-Executive Director 72 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 180,300,967 110,952,541 61.5% 0 0.0% 61.5%
Shareholders
NameEquities%
Hargreaves Lansdown Stockbrokers Ltd. 15,426,000 8.56%
South Ocean Capital Management LLC 10,000,000 5.55%
Acacia Research Corporation 9,841,131 5.46%
Nemean Asset Management LLC 9,420,546 5.22%
Duncan Peyton 8,359,835 4.64%
Alexander James Stevenson 8,317,896 4.61%
Merck & Co., Inc. 8,315,023 4.61%
AllianceBernstein LP 7,661,000 4.25%
Ruffer LLP 5,847,000 3.24%
Lansdowne Partners (UK) LLP 5,463,743 3.03%
Company contact information
4D Pharma Plc
9 Bond Court
3rd Floor
Leeds, Yorkshire LS1 2JZ

Phone : +44.113.895.0130
Web : http://www.4dpharmaplc.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of 4D pharma plc
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
4D PHARMA PLC-32.25%220
GILEAD SCIENCES, INC.20.25%87 579
BIONTECH SE283.45%75 497
WUXI APPTEC CO., LTD.33.61%70 844
REGENERON PHARMACEUTICALS21.38%60 387
VERTEX PHARMACEUTICALS-15.22%51 872
GENMAB A/S13.80%29 283
BEIGENE, LTD.20.82%28 945
ARGENX SE4.83%15 501
HUALAN BIOLOGICAL ENGINEERING INC.-12.90%10 396
NEUROCRINE BIOSCIENCES, INC.-3.06%8 785
MIRATI THERAPEUTICS, INC.-27.22%8 223
FATE THERAPEUTICS, INC.-5.38%8 091
ACCELERON PHARMA INC.-0.74%7 708
ARROWHEAD PHARMACEUTICALS, INC.-10.96%7 111
GW PHARMACEUTICALS PLC89.72%6 907
REMEGEN CO., LTD.4.47%6 391
LEGEND BIOTECH CORPORATION56.00%6 354
ASCENDIS PHARMA A/S-29.91%6 293
DENALI THERAPEUTICS INC.-39.12%6 180
BIOCON LIMITED-17.80%6 128